source
- ArriVent’s phase 3 EGFR inhibitor trial misses primary endpoint, shares plunge 57%ArriVent BioPharma reported results from its phase 3 Furvent trial, which evaluated firmonertinib, a brain-penetrant EGFR inhibitor, in patients with exon 20 insertion-mutated non-small cell lung c…
- Kairos pushes prostate cancer drug ENV-105 into earlier treatment line after promising mid-phase dataKairos Pharma announced a change to its phase 2 trial of ENV-105, a prostate cancer candidate, moving it to an earlier line of therapy. The modified protocol will enroll patients whose PSA rises a…